The company's platform technology induces profound immunostimulation via cationic lipid-DNA complexes, resulting in higher levels of adaptive and innate immune responses compared to other drugs in its class. Their lead product candidate, JVRS-100, is in clinical development as a vaccine adjuvant and immunotherapeutic, and their adjuvanted vaccines and immunotherapeutics enhance the effect of vaccines by increasing the quantity and quality of the immune response while reducing the amount of antigen required in the vaccine, ultimately improving treatment and up-regulating the immune system for patients.